<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387556</url>
  </required_header>
  <id_info>
    <org_study_id>02-0528</org_study_id>
    <nct_id>NCT00387556</nct_id>
  </id_info>
  <brief_title>Ondansetron Reduce Vomiting Associated With Ketamine PSA</brief_title>
  <official_title>Does Ondansetron Reduce the Incidence of Vomiting When Used in Conjunction With Ketamine During Procedural Sedation in the Pediatric Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ondansetron, a commonly used anti-vomiting medication, may reduce the occurrence of vomiting
      associated with ketamine during procedural sedation in the pediatric emergency department.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of vomiting</measure>
    <time_frame>Duration of ED stay and after discharge</time_frame>
    <description>The primary outcomes in this study were vomiting in the ED and after discharge, as determined by telephone follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ED stay</measure>
    <time_frame>Duration of ED stay</time_frame>
    <description>Secondary outcome measures were length of ED stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Sedation</measure>
    <time_frame>Length of ED stay.</time_frame>
    <description>patient or parent satisfaction with their sedation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>Ketamine + Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)</description>
    <arm_group_label>Ketamine + Ondansetron</arm_group_label>
    <arm_group_label>Ketamine + Placebo</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 1-21 years, ASA I or II, fracture of dislocation reduction

        Exclusion Criteria:

          -  age &lt; 1 year, ASA III or IV, hypertension, glaucoma, acute globe injury, increased
             intracranial pressure or central nervous system mass lesion, major psychiatric
             disorder, porphyria, previous adverse reaction to ketamine or ondansetron, parent,
             guardian or patient unwilling to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe E Wathen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Childrens Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>children</keyword>
  <keyword>emesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

